-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FS1EgMq9QIp3ppHDC72xCnblCjeuo+nxIZfD9qCGxm683rHiwcvofx8LEK3EptYq FGccu9qY5D8ncWh7kKzdeQ== /in/edgar/work/20000609/0000916641-00-000832/0000916641-00-000832.txt : 20000919 0000916641-00-000832.hdr.sgml : 20000919 ACCESSION NUMBER: 0000916641-00-000832 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20000609 GROUP MEMBERS: CLINICAL CHEMISTRY HOLDINGS, INC. GROUP MEMBERS: KIRK RANDAL J SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NOVITRON INTERNATIONAL INC CENTRAL INDEX KEY: 0000716646 STANDARD INDUSTRIAL CLASSIFICATION: [3826 ] IRS NUMBER: 042573920 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-39041 FILM NUMBER: 652551 BUSINESS ADDRESS: STREET 1: ONE GATEWAY CENTER STREET 2: SUITE 411 CITY: NEWTON STATE: MA ZIP: 02158 BUSINESS PHONE: 6172619933 MAIL ADDRESS: STREET 1: ONE GATEWAY CENTER STREET 2: SUITE 411 CITY: NEWTON STATE: MA ZIP: 02158 FORMER COMPANY: FORMER CONFORMED NAME: CLINICAL DATA INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KIRK RANDAL J CENTRAL INDEX KEY: 0001091823 STANDARD INDUSTRIAL CLASSIFICATION: [ ] FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: THIRD SECURITY LLC STREET 2: THE GOVERNOR TYLER CITY: RADFORD STATE: VA ZIP: 24141 MAIL ADDRESS: STREET 1: THIRD SECURITY LLC STREET 2: THE GOVERNOR TYLER CITY: RADFORD STATE: VA ZIP: 24141 SC 13D/A 1 0001.txt SCHEDULE 13D AMENDMENT 2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) NOVITRON INTERNATIONAL, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.01 par value per share -------------------------------------- (Title of Class of Securities) 670088103 --------- (CUSIP Number) Third Security, LLC The Governor Tyler 1902 Downey Street Radford, Virginia 24141 Attention: Marcus E. Smith, Esq. Telephone No.: 540-731-3344 --------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: John Owen Gwathmey, Esq. Hunton & Williams Riverfront Plaza, East Tower 951 East Byrd Street Richmond, Virginia 23219 June 8, 2000 ------------ (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), (f) or (g), check the following box [_]. Page 1 of 8 Pages - -------------------------- ------------------------ CUSIP NO. 670088103 13D Page 2 of 8 Pages - -------------------------- ------------------------ - ------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Randal J. Kirk - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ 4 SOURCE OF FUNDS PF - ------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [_] - ------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------ NUMBER OF 7 SOLE VOTING POWER ----------------------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 401,133 ----------------------------------------------------------- OWNED BY 9 SOLE DISPOSITIVE POWER EACH REPORTING ----------------------------------------------------------- PERSON WITH 10 SHARED DISPOSITIVE POWER 401,133 - ------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 401,133 - ------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - ------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.8% - ------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON IN - ------------------------------------------------------------------------------ - -------------------------- -------------------------- CUSIP NO. 670088103 13D Page 3 of 8 Pages - -------------------------- -------------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Clinical Chemistry Holdings, Inc. I.R.S. Identification No.: 52-2202556 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) [_] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER ------------------------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY 398,133 ------------------------------------------------------------- OWNED BY 9 SOLE DISPOSITIVE POWER EACH REPORTING ------------------------------------------------------------- PERSON WITH 10 SHARED DISPOSITIVE POWER 398,133 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 398,133 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 27.6% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- This Amendment No. 2 (the "Amendment") amends and supplements the Statement on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999, as amended by Amendment No. 1 dated March 10, 2000 and filed on March 15, 2000 (the "Original Schedule 13D"), relating to the Common Stock, par value $.01 per share (the "Common Stock"), of Novitron International, Inc., a Delaware corporation (the "Issuer"). Mr. Randal J. Kirk ("Mr. Kirk") and Clinical Chemistry Holdings, Inc., a Delaware corporation that is controlled by Mr. Kirk ("CCH" and, together with Mr. Kirk, the "Reporting Persons"), are filing this Amendment to update the information in the Original Schedule 13D with respect to the beneficial ownership of the Common Stock by the Reporting Persons. Item 3. Source and Amount of Funds or Other Consideration. -------------------------------------------------- Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows: "On February 14, 2000, Mr. Kirk used approximately $1,530 of personal funds to purchase 500 shares of Common Stock, and on February 15, 2000, Mr. Kirk sold 500 shares of Common Stock for approximately $1,470. During the period commencing March 16, 2000 and ending May 2, 2000, CCH used approximately $13,460 of working capital to purchase 4,800 shares of Common Stock. During the period commencing May 5, 2000 and ending May 16, 2000, Kirkfield, L.L.C., a Virginia limited liability company that is controlled by Mr. Kirk ("Kirkfield"), used approximately $9,105 of working capital to purchase 3,000 shares of Common Stock." Item 5. Interest in Securities of the Issuer. ------------------------------------- Item 5(a) of the Original Schedule 13D is hereby amended to read in its entirety as follows: "The aggregate number and percentage of shares of Common Stock to which this statement relates is 401,133 shares, representing 27.8% of the 1,441,925 shares outstanding as reported by the Issuer on February 8, 2000 in the Issuer's Quarterly Report on Form 10-Q for the quarter ended December 31, 1999 (the most recent available filing by the Issuer with the Securities and Exchange Commission). CCH directly beneficially owns 398,133 of the shares to which this statement relates, and Mr. Kirk could be deemed to have indirect beneficial ownership of the shares directly beneficially owned by CCH. Kirkfield directly beneficially owns 3,000 of the shares to which this statement relates, and Mr. Kirk could be deemed to have indirect beneficial ownership of the shares directly beneficially owned by Kirkfield." Item 5(b) of the Original Schedule 13D is hereby amended to read in its entirety as follows: "Each of the Reporting Persons has, together with the other Reporting Person, the shared power to vote or direct the vote and the shared power to dispose or to direct the disposition of 398,133 shares of Common Stock reported by it or him in Item 5(a) hereof. Mr. Kirk has, together with Kirkfield, the shared power to vote or direct the vote and the shared power to Page 4 of 8 Pages dispose or to direct the disposition of 3,000 shares of Common Stock reported by him in Item 5(a) hereof." Item 5(c) of the Original Schedule 13D is hereby amended and supplemented as follows: "The following table lists all transactions in shares of Common Stock by the Reporting Persons that were effected on February 14, 2000, February 15, 2000 and during the period from March 10, 2000, the date on which Amendment No. 1 to this statement was originally filed with the Securities and Exchange Commission, through June 8, 2000. All such transactions were effected on The Nasdaq SmallCap Market.
Shares Purchased Average Price Reporting Person Date (Sold) Per Share* - ---------------------------------------------------------------------------- Mr. Kirk 2/14/00 500 $3.00 Mr. Kirk 2/15/00 (500)** $3.00 CCH 3/16/00 100 $3.00 CCH 4/5/00 2,000 $2.50 CCH 4/13/00 600 $2.88 CCH 4/14/00 1,200 $3.00 CCH 5/2/00 900 $3.00 Mr. Kirk (Kirkfield) 5/5/00 1,200 $3.00 Mr. Kirk (Kirkfield) 5/11/00 500 $3.00 Mr. Kirk (Kirkfield) 5/16/00 1,300 $3.00
* Price excludes commission. ** Reporting Persons have disgorged profits of $1,669.11 to the Issuer related to this sale and the sale by CCH of 10,000 shares of Common Stock on March 13, 2000 in accordance with the requirements of Section 16(b) of the Securities Exchange Act of 1934, as amended." Item 7 Material to be Filed as Exhibits. --------------------------------- The following document is being filed as an exhibit to this Amendment and is incorporated herein by reference: Exhibit 7. Joint Filing Agreement. Page 5 of 8 Pages SIGNATURE --------- After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Date: June 9, 2000 /s/ Randal J. Kirk ------------------------------------ Randal J. Kirk Date: June 9, 2000 CLINICAL CHEMISTRY HOLDINGS, INC. By: /s/ Audrey Ho Ping Ting -------------------------------- Audrey Ho Ping Ting President and Chief Executive Officer Page 6 of 8 Pages EXHIBIT INDEX ------------- Exhibit Number Exhibit - -------------- ------- Exhibit 7. Joint Filing Agreement. Page 7 of 8 Pages EX-7 2 0002.txt JOINT FILING AGREEMENT Exhibit 7 --------- JOINT FILING AGREEMENT ---------------------- In accordance with Rule 13d-1(f) promulgated under the Securities Exchange Act of 1934, as amended, the persons names below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Novitron International, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this agreement as of the 6th day of December, 1999. Date: December 6, 1999 /s/ Randal J. Kirk ------------------------------------ Randal J. Kirk Date: December 6, 1999 CLINICAL CHEMISTRY HOLDINGS, INC. By: /s/ Audrey Ho Ping Ting -------------------------------- Audrey Ho Ping Ting President and Chief Executive Officer Page 8 of 8 Pages -----END PRIVACY-ENHANCED MESSAGE-----